Industries > Pharma > Biological Drug API Manufacturing Services World Industry and Market Predictions 2018-2028

Biological Drug API Manufacturing Services World Industry and Market Predictions 2018-2028

Mammalian Cell Cultures, Microbial Fermentations, Other Expression Systems, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccines

PUBLISHED: 06 July 2018
PAGES: 209
PRODUCT CODE: PHA0322

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE

The biological drug API manufacturing market is estimated to grow at a CAGR of 9.0% in the first half of the forecast period. In 2017, Mammalian cell culture systems submarket represents the largest submarket within the biological drug API manufacturing industry.

How this 209-page report delivers:

• Provides qualitative and quantitative analysis of the leading submarkets the period 2018-2028. Visiongain forecasts revenues and their growth for these submarkets:
• Mammalian cell culture
• Microbial fermentation
• Other expression platforms

Biological Drug API Manufacturing Services World Industry and Market Predictions 2018-2028

• Provides qualitative and quantitative analysis of the leading contract API biological drug applications for the period 2018-2028. Visiongain forecasts contract API drug revenues to 2028 for these individual segments:
• Monoclonal antibody (mAb) therapies
• Vaccines
• Insulin therapies
• Interferon therapies
• Growth hormones

• Find forecasts of the leading national markets from 2018 to 2028:
• The EU, including the five leading markets (UK, Germany, France, Italy and Spain).
• The US
• Japan
• Switzerland
• Emerging markets such as the BRIC (Brazil, Russia, India, and China) countries, South Korea and Singapore.

• Profiles leading global and national companies that offer biotech API manufacturing services to the pharmaceutical industry. For each company, current services offered, recent developments and outlooks are discussed. Leading CMOs profiled in this chapter are:
• Boehringer Ingelheim BioXcellence
• Celltrion
• DSM Biologics
• Lonza
• Samsung BioLogics
• Cytovance Biologics
• Fujifilm Diosynth Biotechnologies
• Operations of leading biopharma companies, such as AbbVie, GSK and Novartis.

• Provides qualitative analysis: SWOT and STEP Analysis of the biological drug API manufacturing market.

• Discover the regulatory outlook for biotech API manufacturing in leading regional and national markets in 2017, as well as predicted developments for the period to 2028.

• Identify important drug development and technology trends that will affect CMOs, their clients and other market participants from 2017. The report also contains SWOT and STEP analysis of the industry and market.

• Find profiles for leading CMOs offering biological drug API manufacturing services to pharmaceutical companies.

• 103 charts unavailable elsewhere

Visiongain’s study is intended for anyone requiring commercial analyses for the biological drug API manufacturing market. You find data, trends and predictions.

Buy our report today Biological Drug API Manufacturing Services World Industry and Market Predictions 2018-2028: Mammalian Cell Cultures, Microbial Fermentations, Other Expression Systems, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccines.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Biological Drug API Manufacturing Services World Industry and Market Predictions 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Biological Drug API Manufacturing Services World Industry and Market Predictions 2018-2028


Latest Pharma news

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

READ

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

READ

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

READ

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

READ

Categories

Category